<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692701</url>
  </required_header>
  <id_info>
    <org_study_id>2020-49</org_study_id>
    <secondary_id>2020-A02119-30</secondary_id>
    <nct_id>NCT04692701</nct_id>
  </id_info>
  <brief_title>Pulvinar Stimulation in Epilepsy: a Pilot Study</brief_title>
  <acronym>PULSE</acronym>
  <official_title>Pulvinar Stimulation in Epilepsy: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep brain stimulation (DBS) is one of the neuromodulation techniques that can be indicated&#xD;
      in patients suffering from refractory epilepsies, especially when an open resection has&#xD;
      failed or is not indicated, and vagal nerve stimulation (VNS) demonstrated no efficacy.&#xD;
      Benefits such as reduction of seizure frequency have been shown for thalamic stimulation of&#xD;
      the anterior thalamic nucleus (ANT), however it has limited efficacy and non-optimal&#xD;
      neurocognitive outcome, making the search for other targets crucial in this context. We&#xD;
      propose a novel target for DBS stimulation in drug-resistant epilepsy namely the medial&#xD;
      pulvinar thalamic nucleus (PuM).&#xD;
&#xD;
      This target has been chosen based on previous retrospective studies demonstrating that PuM is&#xD;
      involved during focal seizures and in loss of consciousness and seizure termination. PuM&#xD;
      stimulation also showed potential encouraging results based on the feasibility and safetu&#xD;
      studies recently published.&#xD;
&#xD;
      The main objective is to obtain a significant percentage of seizure reduction after 12 months&#xD;
      of PuM stimulation compared to baseline period. Quality of life and the relationship with&#xD;
      psychiatric and cognitive comorbidities will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of seizures</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>Events will be recorded using a seizure diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of depression</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>NDDI-E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of anxiety</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>GAD-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of quality of life</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>QOLIE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of epilepsy severity</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>Chalfont</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Pulvinar stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medial pulvinar deep brain stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulvinar deep brain stimulation</intervention_name>
    <description>Stimulation of the medial pulvinar</description>
    <arm_group_label>Pulvinar stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: between 18 and 60 years old&#xD;
&#xD;
          -  Focal or multifocal drug-resistant epilepsy not operable or failure of epilepsy&#xD;
             surgery&#xD;
&#xD;
          -  Vagal nerve stimulation failure (after at least 1 year of treatment or stopped early&#xD;
             for worsening seizures)&#xD;
&#xD;
          -  Either patients with epilepsy whose characteristics suggest that it may respond better&#xD;
             to stimulation of the pulvinar than the anterior thalamic nucleus stimulation (i.e.&#xD;
             posterior quadrant epilepsy, motor/premotor epilepsy, operculo-insular epilepsy,&#xD;
             temporal plus epilepsy, lateral temporal epilepsy) or/and patients with previous&#xD;
             anterior thalamic nucleus stimulation failure (after 2 years of treatment or stopped&#xD;
             early for worsening seizures)&#xD;
&#xD;
          -  Number of seizures &gt; 4 / month during the baseline (3 months) and before the V0 for at&#xD;
             least 3 months&#xD;
&#xD;
          -  Total IQ &gt; 55&#xD;
&#xD;
          -  Give written consent to the study after receiving clear information&#xD;
&#xD;
          -  Be a beneficiary or affiliated to a health insurance plan&#xD;
&#xD;
          -  For women of childbearing potential, a pregnancy test must be negative before&#xD;
             inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Difficulty to read or understand the French language, or inability to understand the&#xD;
             information regarding the study.&#xD;
&#xD;
          -  Generalized epilepsy&#xD;
&#xD;
          -  Presenting contraindication to MRI, a serious intercurrent pathology, a progressive&#xD;
             brain tumor.&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Present a history of attempted suicide in the 6 months prior to inclusion or a score ≥&#xD;
             2 in item 10 of the Montgomery and Asberg Depression Scale (MADRS).&#xD;
&#xD;
          -  Present a surgical or anaesthetic contraindication.&#xD;
&#xD;
          -  Require long-term anticoagulant or platelet aggregation therapy.&#xD;
&#xD;
          -  Hereditary bleeding disorders of coagulation&#xD;
&#xD;
          -  Non obliterated AVM&#xD;
&#xD;
          -  History of Herpes virus brain infection&#xD;
&#xD;
          -  Total IQ below 55.&#xD;
&#xD;
          -  Patients with less than 4 seizures a month&#xD;
&#xD;
          -  To be hospitalized under duress (HO / HDT)&#xD;
&#xD;
          -  Major under guardianship or curatorship&#xD;
&#xD;
          -  Person deprived of liberty by judicial decision&#xD;
&#xD;
          -  Patient currently participating in another clinical trial or having participated in a&#xD;
             clinical trial in the month prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier Arnaud</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Pizzo</last_name>
    <phone>753841613</phone>
    <phone_ext>33</phone_ext>
    <email>francesca.pizzo@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabrice Bartolomei</last_name>
    <email>fabrice.bartolomei@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Neurologie</name>
      <address>
        <city>Nice</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Thomas</last_name>
      <email>thomas.p@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>pulvinar</keyword>
  <keyword>seizures</keyword>
  <keyword>deep brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

